Target intelligence / Profile preview

E3 ubiquitin-protein ligase RNF31 (RNF31)

Target
RNF31
Molecular classification
Enzyme, E3 ubiquitin ligase, RING finger protein, RBR (Ring-between-Ring) protein family
01

Overview

E3 ubiquitin-protein ligase RNF31 (RNF31/HOIP) is an atypical RBR (Ring-between-Ring) family member that acts as the catalytic core of the linear ubiquitin chain assembly complex (LUBAC)[1][3]. It specifically mediates the formation of Met1-linked (linear) polyubiquitin chains, which are crucial for strong NF-κB activation downstream of inflammatory stimuli such as interleukin-1, TNF-α, and Toll-like receptor agonists[1][3]. RNF31 also regulates transcriptional repression of steroidogenic genes by cooperating with DAX-1 and is involved in stabilizing proteins such as estrogen receptor α (ERα) and p53, impacting cell proliferation and apoptosis[2][4]. Dysregulation or overexpression of RNF31 is associated with aggressive cancer phenotypes (breast and liver), poor prognosis, and particular immunodeficiencies and autoinflammatory syndromes[1][3]. The protein contains multiple functional domains (RING, IBR, PUB, and UBA) relevant to substrate interaction and ligase activity, and is being studied as a cancer therapeutic and prognostic biomarker[1][4][3][6]. No approved drugs directly target RNF31, but it is recognized as a potential intervention point for modulating inflammation and tumor progression.

Other names
HOIPZIBRAFLJ10111FLJ23501PaulHOIL-1-interacting proteinIMD115Zinc in-between-RING-finger ubiquitin-associated domain proteinRING finger protein 31RING-type E3 ubiquitin transferase RNF31
02

Mechanism of action

Inhibition of linear ubiquitin chain assembly; Modulation of NF-κB signaling; Disruption of substrate ubiquitination (e.g., estrogen receptor α and p53)

03

Biological functions

UbiquitinationSignal transductionImmune responseTranscriptional regulationRegulation of apoptosisCell proliferationProtein stability
04

Disease associations

CancerImmunodeficiencyInflammationAutoinflammatory disease
05

Safety considerations

Potential risk of immunosuppressionOff-target effects related to broad E3 ligase functionImpact on cell survival pathways and cell cycle regulation
06

Interacting drugs

None identified in current sources (2025) specific to RNF31; research-stage inhibitors may exist.
07

Biomarkers

Elevated RNF31 mRNA/protein (prognostic in aggressive hepatocellular carcinoma and breast cancer)[1]RNF31 germline polymorphisms (risk in lymphoma)[1]

Beyond the preview

Go deeper on E3 ubiquitin-protein ligase RNF31 (RNF31).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on E3 ubiquitin-protein ligase RNF31 (RNF31).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call